IL1B and chronic kidney disease: IL-1β is produced by activation of the inflammasome, and the CANTOS (Canakinumab Anti-inflammatory Thrombotic Outcomes Study) trial revealed that inhibiting IL-1β is promising in ameliorating cardiovascular outcome in both the general population as well as CKD patients [31].